Protagonist Banks $275 Million on FDA Approval of MIMRYLO, Its Second US Clearance of 2026

by Priya Raghunathan · August 31, 2026

Mid-Cap Companies Reporter, The SmallCap Signal

Protagonist Therapeutics said the US Food and Drug Administration approved MIMRYLO, the hepcidin mimetic peptide rusfertide, for erythrocytosis in adults with polycythemia vera, an approval the company said triggers $275 million in near-term payments from partner Takeda. The announcement was dated Aug. 28, according to the company's press release.

The $275 million breaks into two pieces, per that release: a $200 million opt-out fee and a $75 million approval milestone. Protagonist said it remains eligible for up to $875 million in further milestones and for tiered royalties running from 14% to 29% of worldwide net sales, a schedule the company described as producing a weighted average of roughly 21% at $1.5 billion of annual sales.

The structure matters more than the headline number. Protagonist discovered the compound and ran it through Phase 3, then opted out of continued co-funding in April 2026, according to the company. Takeda handled the new drug application and now owns global commercialisation. What Protagonist retains is a claim on someone else's sales effort — lucrative if the launch works, and entirely outside its control if it does not.

What the label covers

MIMRYLO is a weekly subcutaneous injection and is described by both partners as a first-in-class hepcidin mimetic, working on iron regulation rather than on the bone-marrow signalling that existing cytoreductive therapies target. Polycythemia vera is a rare blood cancer; Takeda's own release put the US patient population at roughly 90,000.

The approval rests on the Phase 3 VERIFY study, which Takeda said enrolled 293 patients and compared MIMRYLO plus standard care against placebo plus standard care. The primary endpoint was absence of phlebotomy eligibility. Protagonist reported that 76.9% of patients on MIMRYLO plus standard care achieved a clinical response during weeks 20 through 32, against 32.9% on placebo plus standard care. Secondary endpoints included mean reduction in phlebotomies, maintenance of hematocrit below 45%, and fatigue as measured on the PROMIS Fatigue Short Form 8a.

The safety section is not incidental. Protagonist's release listed injection-site reactions in 56% of patients and anemia in 16%, and flagged warnings for thrombocytosis, injection-site reactions and embryo-fetal toxicity. Andrew T. Kuykendall, a lead investigator quoted in Takeda's release, framed the clearance as giving clinicians a first-in-class option aimed directly at erythrocytosis.

Two approvals, one funding model

Chief executive Dinesh V. Patel, in the company's release, called the approval a paradigm-shifting approach to the management of polycythemia vera. It is the company's second FDA clearance of 2026 by the plain arithmetic of its own announcements: the first came on March 18, when the FDA cleared ICOTYDE (icotrokinra), an oral IL-23 receptor antagonist peptide for moderate-to-severe plaque psoriasis in adults and in patients aged 12 and over weighing at least 40 kg. That approval triggered a $50 million milestone from Johnson & Johnson and carries tiered royalties of 6% to 10% on global net sales plus eligibility for up to $580 million in additional milestones, according to the March release.

The cumulative effect shows in the accounts, though the as-of date matters: the figures below are as of June 30, 2026 and predate the MIMRYLO approval entirely. In its second-quarter report filed Aug. 5, Protagonist recorded $213.5 million of license and collaboration revenue — of which $192.4 million was recognition of the Takeda opt-out payment and $21.1 million development services, per the filing — and GAAP net income of $162.8 million, or $2.29 a diluted share, against research and development expense of $42.1 million and general and administrative expense of $12.6 million. Cash, cash equivalents and marketable securities stood at $849.5 million at June 30, up from $646.0 million at the end of 2025, with total stockholders' equity of $841.5 million. The company said it does not anticipate a near-term equity financing.

That revenue line is milestone recognition, not product sales. Royalty and milestone revenue arrives in steps, and a quarter with no trigger event looks very different from one with two. The further milestone potential the company cites across these two partnered programmes — up to $875 million on rusfertide and up to $580 million on icotrokinra — is contingent on regulatory and sales events that have not happened.

Someone already bought a slice

A third party put a price on the rusfertide stream before the approval landed. On Aug. 12, Zealand Pharma completed the sale of part of its rusfertide economics to Royalty Pharma for $100 million — $50 million at closing and $50 million a year later — according to Zealand's announcement, which described the transaction as closed that day. Zealand's entitlement traces back to a 2012 research collaboration with Protagonist on disulfide-rich peptides, terminated in 2014 and clarified by a 2021 settlement. Under the agreement Royalty Pharma takes a 0.75% royalty on annual global net sales above $1.5 billion while Zealand retains 0.25% above that threshold. Zealand's chief financial officer, Henriette Wennicke, described the deal as converting a potential future royalty stream into immediate capital.

That transaction was struck while the application was still pending, and it is a useful reminder that royalty buyers price probability, not certainty. The threshold both parties negotiated around — $1.5 billion of annual sales — is also the level at which Protagonist's own blended royalty rate is quoted, which gives some sense of where the partners' internal modelling sits.

The tape

US equities were still trading when this article was published. Benzinga's premarket wrap, timestamped 5:37 a.m. ET Monday, showed S&P 500 futures down 0.13% and Dow futures down 0.09%, with Russell 2000 futures up 0.11%, and attributed the softer tone in part to flaring US-Iran tensions. The same wrap put WTI crude at $86.34 a barrel, up 3.45%, and cited CME Group's FedWatch tool showing a 61.9% probability of a Federal Reserve rate increase at the September meeting. On Friday, the last completed session, the Nasdaq Composite closed at 26,402.42, down 0.52%, and the Russell 2000 closed at 2,972.37, down 1.39%.

What to watch from here: Takeda said it is pursuing approvals outside the United States, which would open further regulatory milestones; and the pace of uptake against phlebotomy and existing cytoreductive therapy will determine whether the 14%-to-29% royalty band ever reaches its upper tiers.